Literature DB >> 9493122

Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism.

C G Brilla1, C Scheer, H Rupp.   

Abstract

BACKGROUND: Left ventricular hypertrophy is an adaptive process to increased loading of the left ventricle. This condition becomes pathologic with impaired myocardial function if the various tissue compartments of the myocardium (myocyte, interstitial and vascular compartments) are inhomogeneously altered, particularly if myocardial fibrosis occurs. In arterial hypertension, myocardial fibrosis is known to occur in association with activated circulating or local renin-angiotensin systems and includes reactive perivascular and interstitial fibrosis in both the pressure-overloaded hypertrophied left ventricle and the normotensive non-hypertrophied right ventricle. Therefore, it appears that hemodynamics are not primarily responsible for the adverse myocardial collagen matrix remodeling in hypertensive heart disease. Accordingly, we studied the interaction between cultured adult rat cardiac fibroblasts, which express messenger (m)RNAs for types I and III collagens, the major fibrillar collagens in the heart, and angiotensin II (Ang II), the effector hormone of the renin-angiotensin system.
OBJECTIVES: Specifically, we sought to determine whether Ang II stimulates total collagen synthesis and the expression of type I collagen mRNA in cultured adult rat cardiac fibroblasts, and to investigate the effects of Ang II on intracellular Ca2+ levels.
MATERIALS AND METHODS: Adult rat cardiac fibroblasts were cultured in Dulbecco's Modified Eagle's Medium + 10% fetal calf serum and incubated for 24 h with Ang II with or without specific Ang II type 1 or type 2 receptor antagonists. Collagen synthesis was measured using a 3H-proline incorporation assay, and type I collagen mRNA was determined using reverse-transcriptase polymerase chain reaction. Intracellular Ca2+ transients were measured by fast fluorescence photometry using the fluorescent dye fura-2-acetoxymethylester.
RESULTS: We found a 76% increase in type I collagen mRNA in cultured cardiac fibroblasts after a 24-h incubation with Ang II, and this was abolished by simultaneous incubation with the Ang II type 1 (AT1)-receptor antagonist candesartan. Likewise, total collagen synthesis was stimulated by Ang II in a dose-dependent manner, and this stimulation was also counteracted by candesartan. Additionally, incubation with Ang II resulted in a significant dose-dependent increase in intracellular Ca2+ transients which was also abolished by treatment with candesartan.
CONCLUSIONS: Ang II stimulates collagen synthesis in cultured adult rat cardiac fibroblasts via AT1 receptors, most likely using Ca2+ as a second messenger. These findings suggest a direct interaction between Ang II and cardiac fibroblasts in mediating myocardial fibrosis in arterial hypertension, leading to pathologic left ventricular hypertrophy with initially impaired diastolic and ultimately reduced systolic function of the left ventricle. The AT1-receptor antagonist candesartan cilexetil, which is the prodrug of the active compound candesartan, may prove valuable in preventing or regressing myocardial fibrosis in hypertensive heart disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9493122

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  11 in total

1.  Expression of angiotensin AT(1) and AT(2) receptors in adult rat cardiomyocytes after myocardial infarction. A single-cell reverse transcriptase-polymerase chain reaction study.

Authors:  S Busche; S Gallinat; R M Bohle; A Reinecke; J Seebeck; F Franke; L Fink; M Zhu; C Sumners; T Unger
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Extracellular matrix alterations in cardiomyopathy: The possible crucial role in the dilative form.

Authors:  V I Kapelko
Journal:  Exp Clin Cardiol       Date:  2001

Review 3.  Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations.

Authors:  Anastacia M Garcia; Jonathan-Thomas Beatty; Stephanie J Nakano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-28       Impact factor: 4.733

4.  Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor.

Authors:  M Flores-Muñoz; N J Smith; C Haggerty; G Milligan; S A Nicklin
Journal:  J Physiol       Date:  2010-12-20       Impact factor: 5.182

5.  A novel vascular smooth muscle chymase is upregulated in hypertensive rats.

Authors:  C Guo; H Ju; D Leung; H Massaeli; M Shi; M Rabinovitch
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 6.  Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure.

Authors:  Michikado Iwata; Randy T Cowling; Seon Ju Yeo; Barry Greenberg
Journal:  J Mol Cell Cardiol       Date:  2010-12-13       Impact factor: 5.000

7.  Fibrosis-Related Gene Expression in Single Ventricle Heart Disease.

Authors:  Stephanie J Nakano; Austine K Siomos; Anastacia M Garcia; Hieu Nguyen; Megan SooHoo; Csaba Galambos; Karin Nunley; Brian L Stauffer; Carmen C Sucharov; Shelley D Miyamoto
Journal:  J Pediatr       Date:  2017-10-16       Impact factor: 4.406

8.  Time-course effects of aerobic exercise training on cardiovascular and renal parameters in 2K1C renovascular hypertensive rats.

Authors:  R C A Maia; L E Sousa; R A S Santos; M E Silva; W G Lima; M J Campagnole-Santos; A C Alzamora
Journal:  Braz J Med Biol Res       Date:  2015-08-11       Impact factor: 2.590

9.  Connective tissue growth factor dependent collagen gene expression induced by MAS agonist AR234960 in human cardiac fibroblasts.

Authors:  Arunachal Chatterjee; John Barnard; Christine Moravec; Russell Desnoyer; Kalyan Tirupula; Sadashiva S Karnik
Journal:  PLoS One       Date:  2017-12-29       Impact factor: 3.240

Review 10.  Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers.

Authors:  Camelia R Ban; Stephen M Twigg
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.